Results 141 to 150 of about 4,690 (200)

Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis

Pediatric Pulmonology, 2022
ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of ...
Richard C. De Vuyst, Erin Bennard, Charissa W. Kam, Cameron J. McKinzie, Charles R. Esther   +4 more
openaire   +2 more sources

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (pwCF) aged 2 years and older with at least one F508del-CFTR allele or more. After U.S. approval in 2019, reports emerged of depression-related adverse events in pwCF treated with ELX/TEZ/IVA.
Edward McKone, Marcus Mall
exaly   +3 more sources

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Canadian Journal of Health Technologies, 2022
What Is the CADTH Reimbursement Recommendation for Trikafta? CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met.
openaire   +1 more source

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

European Respiratory Journal, 2023
Graphical abstract Primary respiratory nasal cells help predict the clinical response to elexacaftor/tezacaftor/ivacaftor out-of-label prescription. Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination ...
E. Dréano, Pierre-Régis Burgel, A. Hatton, N. Bouazza, B. Chevalier, J. Macey, Sylvie Leroy, Isabelle Durieu, L. Weiss, D. Grenet, N. Stremler, C. Ohlmann, P. Reix, Michele Porzio, Pauline Roux Claude, N. Rémus, B. Douvry, S. Montcouquiol, L. Cosson, J. Mankikian, Jeanne Languepin, V. Houdouin, L. Le Clainche, A. Guillaumot, D. Pouradier, A. Tissot, P. Priou, L. Mély, F. Chédevergne, M. Lebourgeois, Jean Lebihan, Clémence Martin, Flora Zavala, J. da Silva, L. Lemonnier, Mairead Kelly-Aubert, A. Golec, P. Foucaud, C. Marguet, Aleksander Edelman, A. Hinzpeter, P. de Carli, E. Girodon, I. Sermet-Gaudelus, I. Pranke   +44 more
semanticscholar   +1 more source

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles.

American Journal of Respiratory and Critical Care Medicine, 2022
RATIONALE We recently demonstrated that triple combination CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) improves CFTR function in airway and intestinal epithelia to 40 to 50% of normal in patients with cystic fibrosis (CF ...
S. Graeber, D. Renz, M. Stahl, S. Pallenberg, O. Sommerburg, L. Naehrlich, J. Berges, M. Dohna, F. Ringshausen, F. Doellinger, C. Vitzthum, J. Röhmel, Christine Allomba, S. Hämmerling, S. Barth, C. Rückes-Nilges, M. Wielpütz, G. Hansen, J. Vogel-Claussen, B. Tümmler, M. Mall, A. Dittrich   +21 more
semanticscholar   +1 more source

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients

Journal of Cystic Fibrosis, 2022
Cystic fibrosis (CF) lung transplant (LT) recipients may warrant treatment with elexacaftor/tezacaftor/ivacaftor (ETI) to improve extrapulmonary manifestations of CF. Our objectives were to identify reasons for prescribing ETI after LT and evaluate changes in body mass index (BMI), hemoglobin A1c, hemoglobin, and liver enzymes.This was an electronic ...
Kathleen J. Ramos, Jennifer S. Guimbellot, Maryam Valapour, Lauren E. Bartlett, Travis Hee Wai, Christopher H. Goss, Joseph M. Pilewski, Albert Faro, Joshua M. Diamond   +8 more
openaire   +2 more sources

Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal, 2022
BackgroundAbnormal macrophage function caused by dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) is a critical contributor to chronic airway infections and inflammation in people with cystic fibrosis (PWCF). Elexacaftor/tezacaftor/ivacaftor (ETI) is a new CFTR modulator therapy for PWCF.
Shuzhong Zhang, Chandra L. Shrestha, Frank Robledo-Avila, Devi Jaganathan, Benjamin L. Wisniewski, Nevian Brown, Hanh Pham, Katherine Carey, Amal O. Amer, Luanne Hall-Stoodley, Karen S. McCoy, Shasha Bai, Santiago Partida-Sanchez, Benjamin T. Kopp   +13 more
openaire   +2 more sources

Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor

Pediatric Pulmonology, 2023
AbstractIntroductionReports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized.MethodsRetrospective chart review was used to categorize symptom trajectories of all adults at a single CF Center who initiated
Evelyne Baroud, Nivedita Chaudhary, Anna M. Georgiopoulos   +2 more
openaire   +2 more sources

Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant

Current Opinion in Pulmonary Medicine
Purpose of review In 2019, the United States Food and Drug Administration approved a breakthrough therapeutic for cystic fibrosis, elexacaftor–tezacaftor–ivacaftor (ETI), because of its profound effect on lung function in large phase III clinical trials.
Siddhartha G, Kapnadak, Kathleen J, Ramos   +1 more
openaire   +2 more sources

Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.

Annals of the American Thoracic Society
RATIONALE Limited data exist on safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease.
Pierre-Régis Burgel, J. Paillasseur, Isabelle Durieu, Martine Reynaud-Gaubert, R. Hamidfar, Marlène Murris-Espin, Isabelle Danner-Boucher, Raphael Chiron, Sylvie Leroy, Benoît Douvry, Dominique Grenet, Laurent Mely, Sophie Ramel, Sylvie Moncouquiol, Espérie Burnet, El Hassane Ouaalaya, Philippe Sogni, J. da Silva, Clémence Martin   +18 more
semanticscholar   +1 more source